Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex Extension Study in Uterine Fibroids
NCT01739621Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of telapristone in Uterine Fibroids (UF) (2 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Number of Bleeding Days at 4 months and Uterine Fibroid Symptom Quality of Life Survey at 4 months. Started Sep 2012; status: completed.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT01739621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739621.